Trial
NCT04247594
Dose Escalation Study to Evaluate the Safety, Tolerability, PK and PD of Voxelotor in Patients With SCD
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Pfizer
Collaborators
—
Condition
Sickle Cell Disease
Intervention
Voxelotor
Why stopped
Data will not inform further development of Voxelotor
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-21